Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.
You may also be interested in...
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
UK HTA provisionally tells Roche price for supplying MS blockbuster Ocrevus to the NHS not good enough – 'try again'.